Arcturus Therapeutics

Arcturus Therapeutics News & Events

Arcturus Therapeutics Appoints Robert Baltera and Stuart Collinson, Ph.D. to its Board of Directors

May 6, 2014

Immediate Release Biotech Leadership with Significant Strategic and Financial Expertise San Diego, Calif., May 6, 2014 – Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, announced today the appointment of two new members to its Board of Directors. The new directors, Robert Baltera and Stuart Collinson, Ph.D., bring considerable biotech experience to […]

Arcturus Therapeutics to Present at the 13th Annual Needham Healthcare Conference

April 7, 2014

Immediate Release San Diego, Calif., April 7, 2014 – Arcturus Therapeutics, Inc., a preclinical-stage RNA medicines company pursuing rare diseases, today announced its President & CEO, Joseph E. Payne, has been invited to present at the 13th Annual Needham Healthcare Conference 2014, being held April 8 – 9 at The Westin Grand Central Hotel in […]

Arcturus Therapeutics to Present at the BIO-Europe Spring Partnering Conference

March 10, 2014

Immediate Release – In Vivo Delivery of RNA Medicines to Multiple Tissues Utilizing its Proprietary LUNARTM Delivery Technology – San Diego, Calif., March 10, 2014 – Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced that it has been selected to present at BIO-Europe Spring Partnering Conference 2014, being held March […]

Arcturus Therapeutics to Present RNAi Data for Orphan Diseases Utilizing the LUNARTM Technology Platform at BIOCOM’s Global Life Science Partnering Conference

February 24, 2014

Immediate Release San Diego, Calif., February 24, 2014 – Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, today announced it will present at BIOCOM’s Global Life Science Partnering Conference being held on February 26 and 27, 2014 at the Lodge in Torrey Pines, La Jolla, California. In addition to providing an update […]

Arcturus Therapeutics to Present at the Keystone Symposia Conference on RNA Silencing

January 30, 2014

Immediate Release Arcturus Therapeutics to Present at the Keystone Symposia Conference on RNA Silencing – Arcturus proprietary LUNARTM delivery technology demonstrates exceptional potency in vivo, ED50 of 0.020 mg/kg – No adverse events observed in a multiple-dose rat toxicology study, up to 30 mg/kg – Functional in vivo delivery of distinct therapeutic classes of RNA, […]

Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program

January 13, 2014

Immediate Release Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program New Preclinical Results in Non-Human Primates Demonstrate Significant and Sustained Reduction of Transthyretin Using its Proprietary LUNARTM Delivery Technology SAN DIEGO, CA – January 13th, 2014 – Arcturus Therapeutics, Inc., an industry leader in RNA technologies, today announced its […]

Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014

January 7, 2014

FOR IMMEDIATE RELEASE Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014 SAN DIEGO, CA – January 7, 2014 – Arcturus Therapeutics, Inc., an industry leader in RNA technologies for the treatment of rare orphan diseases, today announced that Joseph E. Payne, President & CEO will be presenting at the Biotech Showcase in San […]

Arcturus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., as Chief Business Officer

October 28, 2013

FOR IMMEDIATE RELEASE SAN DIEGO, Calif., October 28, 2013 – Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of rare orphan diseases, today announced the expansion of its management team with the appointment of Zachary A. Zimmerman, Ph.D., as chief business officer. Dr. Zimmerman will be responsible for defining Arcturus’ corporate […]

Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014

October 21, 2013

FOR IMMEDIATE RELEASE SAN DIEGO, Calif., October 21, 2013 – Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of rare orphan diseases, today announced it has secured $5 million in a Series A funding round led by multiple private capital, high net-worth investors from Canada, Japan and the United States. The […]